Ivera 6
Ivermectin selectively binds and with high affinity to glutamate-gated chloride ion channels, which occur in invertebrate nerve and muscle cells leading to an increase in the permeability of cell membranes to chloride ions with hyperpolarization of the nerve or muscle cell and, ultimately, death of the parasite.
Ivermectin selectively binds and with high affinity to glutamate-gated chloride ion channels, which occur in invertebrate nerve and muscle cells leading to an increase in the permeability of cell membranes to chloride ions with hyperpolarization of the nerve or muscle cell and, ultimately, death of the parasite.
Ivermectin selectively binds and with high affinity to glutamate-gated chloride ion channels, which occur in invertebrate nerve and muscle cells leading to an increase in the permeability of cell membranes to chloride ions with hyperpolarization of the nerve or muscle cell and, ultimately, death of the parasite.
Dosage & Administration
Adult & Elderly: One tablet a day before or after a meal (food independent absorption) or as directed by the physician. In more severe cases, two tablets a day may be required as prescribed by the physician.
Pediatric patients: Safety and effectiveness in pediatric patients have not been established.
Interaction
Post-marketing reports of increased INR (International Normalized Ratio) have been rarely reported when ivermectin was co-administered with warfarin.
Contraindications
It is contraindicated in patients who are hypersensitive to any component of this product.
Side Effects
Strongyloidiasis: In four clinical studies involving a total of 109 patients given either one or two doses of 170 to 200 mcg/kg of Ivermectin, the following adverse reactions were reported as possibly, probably, or definitely related to Ivermectin.
Body as a whole: asthenia/fatigue (0.9%), abdominal pain (0.9%)
Gastrointestinal: anorexia (0.9%), constipation (0.9%), diarrhea (1.8%), nausea (1.8%), vomiting (0.9%) Nervous System/Psychiatric: dizziness (2.8%), somnolence (0.9%), vertigo (0.9%), tremor (0.9%)
Skin: pruritus (2.8%), rash (0.9%), and urticaria (0.9%).
Pregnancy & Lactation
Pregnancy Classification C. Ivera 6 does not appear to be fetotoxic to a growing fetus in any way. However, no suitable and well-controlled studies in pregnant women have been conducted. Because the safety of ivermectin in pregnancy has not been proved, it should not be used during pregnancy.
Ivera 6 is excreted in low amounts in human milk by nursing mothers. Treatment of lactating mothers should be conducted only when the danger of delayed treatment to the mother surpasses the potential risk to the newborn.
Precautions & Warnings
Microfilaricidal medicines, such as diethylcarbamazine citrate (DEC-C), have been documented in the past to elicit cutaneous and/or systemic reactions of different severity (the Mazzotti reaction) as well as ophthalmological reactions in onchocerciasis patients. These reactions are most likely allergic and inflammatory responses to microfilariae death. These events may occur in patients treated with Ivermectin for onchocerciasis, in addition to clinical adverse effects that are maybe, probably, or definitely connected to the medicine. There haven't been any controlled clinical trials on the treatment of severe Mazzotti responses.
Therapeutic Class
Anthelmintic
Storage Conditions
Do not store at temperatures above 30°C. Keep out of children's reach.